Clinical Trials on Estrogen Receptor-positive Breast Cancer

Total 12168 results

Eisai Inc.

Completed

Trial of H3B-6545, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer

Breast Cancer | Breast Neoplasms | Cancer, Breast | Breast Cancer Female | Estrogen Receptor Positive Tumor | Breast Adenocarcinoma | ER Positive | Estrogen-receptor Positive Breast Cancer

France, United Kingdom, United States
University of Washington
National Cancer Institute (NCI)

Completed

Combination Chemotherapy and Filgrastim Before Surgery in Treating Patients With HER2-Positive Breast Cancer That Can Be Removed By Surgery

HER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...

United States
National Cancer Institute (NCI)

Terminated

Lapatinib Ditosylate and Akt Inhibitor MK2206 in Treating Women With Metastatic Breast Cancer

Stage IV Breast Cancer | Recurrent Breast Carcinoma | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Positive | Progesterone Receptor Negative | Progesterone Receptor Positive

United States
Syndax Pharmaceuticals

Completed

Study to Evaluate Exemestane With and Without Entinostat (SNDX-275) in Treatment of Postmenopausal Women With Advanced Breast Cancer (ENCORE301)

Breast Cancer | ER+ Breast Cancer | Estrogen Receptor-Positive Breast Cancer | Breast Cancer, Estrogen Receptor-Positive

United States, Czechia, Canada, Hungary, Russian Federation
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI); Genentech, Inc.; Translational Breast Cancer... and other collaborators

Terminated

Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer

Stage IV Breast Cancer | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Negative | Progesterone Receptor Negative | Progesterone Receptor Positive | Triple-Negative Breast Carcinoma

United States
City of Hope Medical Center
National Cancer Institute (NCI); Merck Sharp & Dohme LLC

Completed

Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer

Stage IV Breast Cancer | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Negative | Progesterone Receptor Negative | Progesterone Receptor Positive | Triple-Negative Breast Carcinoma

United States
National Cancer Institute (NCI)

Terminated

MK2206 in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer

Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Negative | HER2/Neu Positive | Progesterone Receptor Negative | Progesterone Receptor Positive and other conditions

United States
Istituto Scientifico Romagnolo per lo Studio e...

Terminated

A Phase II Study Evaluating the Role of Androgen Receptors as Targets for Therapy of Pre-treated Post-menopausal Patients With ER/PgR-negative/AR-positive or ER and/or PgRpositive/ AR-positive Metastatic Breast Cancer (ARTT) (ARTT)

Estrogen Receptor Positive Breast Cancer | Androgen Receptor Gene Overexpression | Progesterone Receptor Positive Tumor | Metastatic Breastcancer | Estrogen Receptor Negative Neoplasm | Progesterone Receptor Negative Neoplasm

Italy
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer

Inflammatory Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage IIIB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast Cancer

United States
National Cancer Institute (NCI)

Completed

Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer

Recurrent Breast Carcinoma | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Negative | HER2/Neu Positive | Progesterone Receptor Negative | Progesterone Receptor Positive | Stage IIIC Breast Cancer AJCC v6 | Stage IV Breast Cancer AJCC v6 and v7

United States, Puerto Rico
Oana Danciu, MD
Pfizer; Big Ten Cancer Research Consortium

Active, not recruiting

Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer

Metastatic Breast Cancer | Hormone Receptor Positive Malignant Neoplasm of Breast | Human Epidermal Growth Factor 2 Negative Carcinoma of Breast | Estrogen Receptor Positive Breast Cancer | Progesterone Receptor Positive Tumor

United States
National Cancer Institute (NCI)

Completed

Anastrozole and ZD1839 Compared With Fulvestrant and ZD1839 in Postmenopausal Women w/ Metastatic Breast Cancer

Stage IV Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-positive Breast Cancer

United States
Northwestern University
National Cancer Institute (NCI); MedImmune LLC; Avon Breast Cancer Foundation

Completed

MEDI4736 and Tremelimumab in Treating Patients With Metastatic HER2 Negative Breast Cancer

Stage IV Breast Cancer | Recurrent Breast Carcinoma | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Negative

United States
National Cancer Institute (NCI)

Terminated

RO4929097 and Letrozole in Treating Post-Menopausal Women With Hormone Receptor-Positive Stage II or Stage III Breast Cancer

Stage II Breast Cancer | Stage IIIA Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-positive Breast Cancer | HER2-negative Breast Cancer

United States
Fudan University

Recruiting

Neoadjuvant With Trastuzumab, Pyrotinib Plus Palbociclib and Fulvestrant in HER2-positive, ER-positive Breast Cancer (NeoTPPF)

HER2-positive Breast Cancer | Estrogen Receptor-positive Breast Cancer

China
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Letrozole and Imatinib Mesylate in Treating Postmenopausal Participants With Estrogen or Progesterone Positive Metastatic Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Estrogen Receptor Positive | Progesterone Receptor Positive | Postmenopausal | KIT Positive | PDGFR Positive

United States
Alliance Foundation Trials, LLC.
Pfizer; Syneos Health; UNICANCER; German Breast Group; SOLTI Breast Cancer Research... and other collaborators

Active, not recruiting

Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer (PATINA)

HER-2 Positive Breast Cancer | Estrogen Receptor Positive Breast Cancer

United States, Spain, France, Italy, Germany, Australia, Portugal, New Zealand
National Cancer Institute (NCI)

Completed

F-18 16 Alpha-Fluoroestradiol-Labeled Positron Emission Tomography in Predicting Response to First-Line Hormone Therapy in Patients With Stage IV Breast Cancer

Stage IV Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast Cancer

United States
First Affiliated Hospital of Zhejiang University

Recruiting

Dalpiciclib in Combination With Exemestane and Trastuzumab Plus Pyrotinib in Early Triple Positive Breast Cancer

Breast Cancer | HER2-positive Breast Cancer | Estrogen Receptor Positive Tumor

China
University Hospital, Tours
Institut Cancerologie de l'Ouest

Terminated

A Randomised Study of Docosahexaenoic Acid (DHA) in Metastatic Breast Cancer (DHALYA)

Metastatic Breast Cancer | Estrogen Receptor Positive Tumor | Progesterone Receptor Positive Tumor | HER-2 Negative Tumor

France
University of Nebraska
National Cancer Institute (NCI)

Active, not recruiting

Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer

Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Invasive Breast Carcinoma | Stage IA Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Negative | HER2/Neu Positive | Progesterone... and other conditions

United States
Virginia Commonwealth University
National Cancer Institute (NCI); Merck Sharp & Dohme LLC

Active, not recruiting

Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca

Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Invasive Breast Carcinoma | Stage IIA Breast Cancer | Stage IIB Breast Cancer | HER2/Neu Negative | Progesterone Receptor Negative | Estrogen Receptor-positive Breast Cancer | Breast Adenocarcinoma | Progesterone Receptor Positive... and other conditions

United States
ETOP IBCSG Partners Foundation
Pfizer; Hoffmann-La Roche

Completed

To Reduce the Use of Chemotherapy in Postmenopausal Patients With ER-positive and HER2-positive Breast Cancer (TOUCH) (TOUCH)

Breast Cancer | HER2-positive Breast Cancer | Estrogen Receptor Positive Tumor

France, Switzerland, Belgium, Italy
University of Arizona
National Cancer Institute (NCI)

Completed

Pilot Study Estradiol Followed by Exemestane Hormone Receptor + Metastatic Breast Cancer

Stage IV Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor Positive Tumor

United States
University of Washington
National Cancer Institute (NCI)

Terminated

Hormone Therapy and Combination Chemotherapy Before and After Surgery in Treating Patients With Stage I-IIIA Breast Cancer

Stage I Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-positive Breast Cancer | HER2-negative Breast Cancer

United States
University of Utah

Recruiting

[18F]Fluoroestradiol-PET/CT Companion Imaging Study to the FORESEE Trial

Estrogen Receptor Positive Breast Cancer

United States
Vanderbilt-Ingram Cancer Center

Active, not recruiting

A 2-Week Ketogenic Diet in Combination With Letrozole to Modulate PI3K Signaling in ER+ Breast Cancer

Estrogen Receptor-positive Breast Cancer

United States
National Cancer Institute (NCI)

Withdrawn

Fulvestrant and Palbociclib With or Without Copanlisib in Treating Patients With Hormone Receptor Positive, HER2 Negative, Stage IV Breast Cancer

Estrogen Receptor Positive | HER2/Neu Negative | Progesterone Receptor Positive | Stage IV Breast Cancer AJCC v6 and v7
Mayo Clinic
National Cancer Institute (NCI)

Completed

Alisertib and Fulvestrant in Treating Patients With Hormone Receptor Positive Breast Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery

Stage IV Breast Cancer | Recurrent Breast Carcinoma | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor Positive | Progesterone Receptor Positive

United States
Polly A. Niravath, MD

Recruiting

REVIVE: Replens Versus Intra-Vaginal Estrogen for the Treatment of Vaginal Dryness on Aromatase Inhibitor Therapy (REVIVE)

Breast Cancer | Estrogen Receptor Positive Breast Cancer

United States
Queen Mary University of London
Hoffmann-La Roche; Asan Medical Center; Kliniken Essen-Mitte; MedSIR

Completed

Pre-operative Immunotherapy Combination Strategies in Breast Cancer (ECLIPSE)

Breast Cancer | Estrogen Receptor-positive Breast Cancer

United Kingdom
AHS Cancer Control Alberta

Active, not recruiting

A Study to See Whether Estrogen Can Slow the Growth of Some ER Positive Breast Cancers (PRESTO)

Estrogen Receptor Positive Breast Cancer

Canada
University of Pittsburgh Medical Center

Completed

Electronic Medical Record-Based Nudge to Reduce SLNB

Breast Cancer | Estrogen-receptor-positive Breast Cancer

United States
Velindre NHS Trust
AstraZeneca; Cardiff and Vale University Health Board; Covance; Cenduit LLC

Active, not recruiting

Fulvestrant +/- Akt Inhibition in Advanced Aromatase Inhibitor Resistant Breast Cancer (FAKTION)

Estrogen Receptor Positive Breast Cancer

United Kingdom
University of Virginia

Withdrawn

COX Inhibition and Biomarkers During Neoadjuvant Chemoendocrine Therapy for ER+, HER2- Stage I-III Breast Cancer (Breast 51)

Breast Cancer | Estrogen Receptor-positive Breast Cancer

United States
The Methodist Hospital Research Institute
Millennium Pharmaceuticals, Inc.

Completed

TAK-228 Plus Tamoxifen in Patients With ER-Positive, HER2-negative Breast Cancer (ANETT)

Estrogen Receptor Positive Breast Cancer

United States
Queen Mary University of London
AstraZeneca

Unknown

A Randomized Study of AZD2014 in Combination With Fulvestrant in Metastatic or Advanced Breast Cancer (MANTA)

Estrogen Receptor Positive Breast Cancer

Spain, United Kingdom, France, Portugal, Georgia, Korea, Republic of, Germany, Hungary, Romania
Western Regional Medical Center

Terminated

Hydroxychloroquine in Metastatic Estrogen Receptor-Positive Breast Cancer Progressing on Hormonal Therapy (ABC01)

Estrogen Receptor Positive Breast Cancer

United States
Gangnam Severance Hospital
Seoul National University

Recruiting

OFS in Premenopausal Node+ Breast Cancer With Low Genomic Risk (INTERSTELLAR)

Breast Cancer | HER2-negative Breast Cancer | Estrogen Receptor Positive Tumor | Premenopausal Breast Cancer | Node-positive Breast Cancer

Korea, Republic of
Seoul National University Hospital

Active, not recruiting

Breast Density Change Predicting Response to Adjuvant Aromatase Inhibitor (DEAR)

Invasive Breast Cancer | Estrogen Receptor Positive Breast Cancer

Korea, Republic of
Cairo University

Unknown

Letrozole and Metronomic Capecitabine in ER-positive HER2 Negative Advanced Breast Cancer (B-001 Study) (B-001)

Breast Cancer | Metastatic Breast Cancer | Estrogen Receptor-positive Breast Cancer

Egypt
Northwestern University
National Cancer Institute (NCI)

Not yet recruiting

Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer

Metastatic Breast Cancer | Estrogen-receptor-positive Breast Cancer | HER2/Neu-Negative Breast Cancer | Advanced Breast Cancerv

United States
Baylor Breast Care Center

Recruiting

Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer (RESPONSE)

Breast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer Invasive

United States
Aarhus University Hospital
Odense University Hospital; Rigshospitalet, Denmark; University of Copenhagen; Herning... and other collaborators

Recruiting

The MASTER Study (MAmmary Cancer STatin ER Positive Study)

Breast Cancer Female | Estrogen Receptor Positive Tumor

Denmark
Gilead Sciences

Terminated

GS-5829 in Combination With Fulvestrant or Exemestane in Women With Advanced Estrogen Receptor Positive, HER2 Negative-Breast Cancer

Advanced Estrogen Receptor Positive HER2- Breast Cancer

United States
Duke University
United States Department of Defense

Completed

Evaluation of Endocrine Therapy Effects of Host Immunity in Early Stage Breast Cancer

Healthy | Breast Cancer | Estrogen Receptor-positive Breast Cancer

United States
First Affiliated Hospital Xi'an Jiaotong University

Unknown

The Value of 18F-FES-PET/CT in Predicting Fulvestrant Efficacy in Breast Cancer (PET)

Estrogen Receptor-positive Breast Cancer | Fulvestrant

China
Eisai Inc.

Completed

Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer

Breast Cancer | Estrogen Receptor Positive Tumor

United States
Inova Health Care Services
City of Hope Medical Center

Recruiting

Systems Biology Guided Therapy for Breast Cancer Positive for Oestrogen Receptor After Aromatase Inhibitor and CDK Inhibition (SPOCK)

Breast Cancer | Estrogen Receptor-positive Breast Cancer | HER2-negative Breast Cancer

United States
Dana-Farber Cancer Institute
Johns Hopkins University; Translational Breast Cancer Research Consortium

Not yet recruiting

The SAPPHO Study: A Single-Arm, Phase II Study of Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer

Breast Cancer | HER2-positive Breast Cancer | Stage IV Breast Cancer | Breast Cancer Female | Breast Cancer Metastatic | Estrogen Receptor-positive Breast Cancer

United States

Clinical Trials on Estrogen Receptor-positive Breast Cancer

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Papua New Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations